Biotech
Freenome
Freenome raises $254M Series D at $1.2B valuation
$254M
Total Raised
Series D
Latest Round
2014
Founded
300+
Employees
South San Francisco, CA
1 min read
Quick Facts
Valuation
$1.2B
Latest Round Size
$254M
Latest Round Date
February 2024
Freenome: Series D Funding Round
Freenome has successfully raised $254M in Series D funding, reaching a valuation of $1.2B.
Company Overview
Multi-cancer early detection blood test developer using AI
Funding Details
The Series D round was led by Roche, with participation from a16z Life Sciences, ARK Investments.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2014
- Employees: 300+
- Category: Biotech
Investment
Freenome plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Roche: Verified investor in Series D
- a16z Life Sciences: Verified investor in Series D
- ARK Investments: Verified investor in Series D
Key Investors
Roche
Lead Investor
Verified investor in Series D
a16z Life Sciences
Investor
Verified investor in Series D
ARK Investments
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
Editorial Team
Oct 8, 2025
1 min read•$153M